Description
SWOT ANALYSIS OF BAYER GROUP
Bayer Group
Parent Company
Bayer group
Category
Diversified Chemical
Sector
Industrial products
Tagline/ Slogan
Science for a better life
USP
Innovative pharmaceutical products like genetically engineered product
STP
Segment
Health Care segment, Agriculture, Polymers and Chemicals segments
Analgesics, cardiovascular risk prevention, cough & cold, dermatology, gastrointestinal and nutritionals health care, animal health care, Seed Target Group treatment and pest prevention
Positioning
Worldwide leading position in therapeutic drugs area
SWOT Analysis
1. Comprehensive portfolio of chemical, material science, healthcare and agricultural products 2. Bayer remains vastly dominant in pediatric vitamins and dietary supplements with 25% value share 3. Diversified supply process in conjunction with long-term supply agreements minimize the company’s exposure to production process risk 4. Presence in diversified streams offers protection against demand fluctuations Strength 5. Strong brand presence in the industry and strong financials
1. Allegations against the group on price fixing has tarnished the brand image 2. Shown in bad light over patent infringements and lawsuits 3. Biotech products segment affected by risk due to highly complex Weakness manufacturing process
Opportunity
1. High potential drugs like Xarelto, Stivarga, Eylea, Xofigo &Riociguat
2. Joint ventures and acquisitions will increase market presence 3. Growing demand in crop industry
1. Weak global economy and problems in pharmaceutical industries can hamper growth 2. Bayer's revenue growth may be impacted negatively by Regulatory controls on pharmaceutical product prices Threats 3. Low cost substitutes
Competition
1. GlaxoSmithKline Plc. 2. Johnson & Johnson 3. Abbott Laboratories 4. Novartis AG Competitors 5. Pfizer Inc.
doc_924225090.docx
SWOT ANALYSIS OF BAYER GROUP
Bayer Group
Parent Company
Bayer group
Category
Diversified Chemical
Sector
Industrial products
Tagline/ Slogan
Science for a better life
USP
Innovative pharmaceutical products like genetically engineered product
STP
Segment
Health Care segment, Agriculture, Polymers and Chemicals segments
Analgesics, cardiovascular risk prevention, cough & cold, dermatology, gastrointestinal and nutritionals health care, animal health care, Seed Target Group treatment and pest prevention
Positioning
Worldwide leading position in therapeutic drugs area
SWOT Analysis
1. Comprehensive portfolio of chemical, material science, healthcare and agricultural products 2. Bayer remains vastly dominant in pediatric vitamins and dietary supplements with 25% value share 3. Diversified supply process in conjunction with long-term supply agreements minimize the company’s exposure to production process risk 4. Presence in diversified streams offers protection against demand fluctuations Strength 5. Strong brand presence in the industry and strong financials
1. Allegations against the group on price fixing has tarnished the brand image 2. Shown in bad light over patent infringements and lawsuits 3. Biotech products segment affected by risk due to highly complex Weakness manufacturing process
Opportunity
1. High potential drugs like Xarelto, Stivarga, Eylea, Xofigo &Riociguat
2. Joint ventures and acquisitions will increase market presence 3. Growing demand in crop industry
1. Weak global economy and problems in pharmaceutical industries can hamper growth 2. Bayer's revenue growth may be impacted negatively by Regulatory controls on pharmaceutical product prices Threats 3. Low cost substitutes
Competition
1. GlaxoSmithKline Plc. 2. Johnson & Johnson 3. Abbott Laboratories 4. Novartis AG Competitors 5. Pfizer Inc.
doc_924225090.docx